Murphy discussed the secondary end point of equivocal findings on PSMA PET/CT from the proPSMA study presented at the SUO 21st Annual Meeting.
Declan Murphy
Advertisement
Articles by Declan Murphy
Declan Murphy, MB, BCh, shares his thoughts on the potential for prostate-specific membrane antigen PET/CT to impact outcomes for patients with localized and high-risk prostate cancers.
Declan Murphy discusses the accuracy findings from the proPSMA study presented at the 2020 SUO Meeting.
Declan Murphy discusses the motivation behind the proPSMA study and the emerging history of PSMA PET/CT to challenge conventional imaging at the 2020 SUO Meeting.
Declan Murphy talked about the future of PSMA theranostics to target metastatic castration-resistant prostate cancer.
Advertisement
Latest Updated Articles
Comparing Accuracy Findings from the proPSMA Study for PSMA PET/CT and Conventional ImagingPublished: December 24th 2020 | Updated:
Declan Murphy on PSMA Molecules and the Motivation Behind the proPSMA TrialPublished: December 14th 2020 | Updated:
Declan Murphy on Theranostics and Future of PSMA PET/CT for Prostate CancerPublished: December 10th 2020 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
2
Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC
3
Sacituzumab Tirumotecan Improves Survival in Second-Line EGFR+ NSCLC
4
Adjuvant Therapy Confers Postoperative ctDNA Clearance, DFS Benefit in CRC
5
